Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 4/20 | 0.56 |
| ▸ | NAAA | Q02083 | 1/20 | 0.55 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | SELP | P16109 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21761818 | 0.94 | FAAH (0.65) | CASP2FAAHNAAADNM1LPAR1 | |
| SCHEMBL9549395 | 0.92 | FAAH (0.68) | CASP2FAAHNAAADNM1LPAR1 | |
| SCHEMBL27360878 | 0.92 | FAAH (0.68) | CASP2FAAHNAAADNM1LPAR1 | |
| SCHEMBL115428 | 0.92 | FAAH (0.68) | CASP2FAAHNAAADNM1LPAR1 | |
| SCHEMBL115888 | 0.92 | FAAH (0.68) | CASP2FAAHNAAADNM1LPAR1 | |
| SCHEMBL23005324 | 0.92 | FAAH (0.68) | CASP2FAAHNAAADNM1LPAR1 | |
| SCHEMBL114457 | 0.92 | FAAH (0.68) | CASP2FAAHNAAADNM1LPAR1 | |
| SCHEMBL18738989 | 0.92 | FAAH (0.68) | CASP2FAAHNAAADNM1LPAR1 | |
| SCHEMBL118328 | 0.92 | FAAH (0.68) | CASP2FAAHNAAADNM1LPAR1 | |
| SCHEMBL14576780 | 0.91 | CASP2 (0.68) | CASP2FAAHNAAADNM1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023113457-A1 | NOVEL COMPOUND FOR DEGRADING TARGET PROTEIN OR POLYPEPTIDE BY USING POLYUBIQUITINATION | (주)프레이저테라퓨틱스 | 2023-06-22 | — | — | WO | disclosed |
| EP-2701510-B1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE INC (US) | 2017-02-15 | — | — | EP | disclosed |
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | IL17A, IL15, IL2 | CASP2 629/4885FAAH 3933/4885NAAA 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.